Given the study’s limitations—including a modest sample size, single-center design, and short observation period—future large-scale, multicenter, and long-term studies are warranted to confirm these associations and further explore the clinical utility of sCD36 and CD36-related pathways in the personalized management of DKD. The gene discussed is CD36; the disease is diabetic kidney disease.